ZYXEL
Türk Telekom, pioneer of digital transformation Türkiye, has completed the world’s first mass deployment of Software-Defined Fiber Broadband. By using Netsia’s BB Suite and Zyxel’s Whitebox OLT, Türk Telekom has taken an important step towards fulfilling its virtualized and disaggregated broadband network strategy and thus, providing world-class, modern, high quality and high-speed broadband services.
“Beyond our role as a telecommunications operator, we are leading Türkiye's ambition to become a significant player in technology exports through our pioneering initiatives and partnerships. While supporting our local ecosystem through collaborations within our country, we are also elevating the prestige and value of our nation through our global endeavors," says Ümit Önal, CEO at Türk Telekom. “The cutting-edge fiber infrastructure technology product Zyxel, developed by Argela, our company renowned for innovative solutions, along with its US subsidiary Netsia, has evolved into an innovation that sets global standards. We are delighted to contribute to our country's vision of becoming a technology-exporting nation through the contract we have signed with Zyxel.”
Zyxel and Netsia have successfully completed the integration of Zyxel’s SDA Series Combo Whitebox OLT with Netsia’s BB Suite to realize the fully disaggregated broadband access network. The integrated solution has been tested in Türk Telekom’s live network and is now ready for deployment by all service providers globally. The partnership was made official with a contract signing ceremony held at this year’s Mobile World Congress on February 27. In attendance for the signing ceremony was Republic of Türkiye Deputy Transport and Infrastructure Minister Ömer Fatih Sayan.
The Netsia BB Suite provides network operators with an open, multi-vendor platform based on open-source SEBA project and BBF data models. Netsia BB Suite enables network operators to extend software defined programming to the fixed access network with customized support for each operator’s unique services and workflows. By enabling a fully disaggregated network, service providers are no longer committed to one vendor to fulfill all their needs. Instead, they have full flexibility to choose products and partners that work best for them, while having the flexibility to customize the solution to their needs.
Türk Telekom chose Zyxel’s Multi SDA products , which are all-in-one PON Whitebox OLT’s that are fully equipped to provide scalability, flexibility and interoperability to the Netsia BB Suite. The OLT’s have features that simultaneously support XGS-PON, GPON and Combo PON technologies, designed to make it easier for operators to adopt new technologies that integrate seamlessly with this solution.
“Netsia’s BB Suite is one of the most mature versatile solutions in the market, and our SDA Series Combo is designed to jointly further the network disaggregation evolution,” says Karsten Gewecke, President at Zyxel Communications. “We wanted to develop a flexible, future proof solution that creates an open broadband-access environment with vendor-agnostic hardware, keeping service providers ahead of the competition.”
Netsia CEO C. Bora Eliaçık says: “Türk Telekom, a globally recognized leader in telecommunications, is at the forefront of innovation in the Software-defined Fiber Broadband arena. We are honored to partner with them on this transformative journey. Our Netsia BB Suite product is designed to revolutionize how operators manage their access networks by providing a unified, powerful management solution. This collaboration marks a significant milestone in the evolution of access network management.” Eliaçık adds: “Our BB Suite allows the broadband access network to adapt itself to different service requirements and customer experience needs. The solution also supports the operators to optimize the CAPEX and OPEX costs by breaking the vendor lock, allowing more controllable and flexible PON networks and thus enabling critical features and services in the network. Our cooperation with Zyxel is extremely fruitful and we thank them for their collaboration and look forward to continuing our successful partnership.”
About Türk Telekom:
Türk Telekom, with over 180 years of history, is the first integrated telecommunications operator in Türkiye. Having a wide service network and product range in the fields of individual and corporate services, Türk Telekom unified its mobile, internet, phone and TV products and services under the single “Türk Telekom” brand. “Türkiye’s Multiplay Provider” Türk Telekom has 17.4 million fixed access lines, 15.1 million fixed broadband, 26.1 million mobile and 2.9 million TV subscribers as of September 30, 2023. Türk Telekom Group Companies provide services in all 81 cities of Türkiye with nearly 38.000 employees with the vision of introducing new technologies to Türkiye and accelerating Türkiye’s transformation into an information society. www.turktelekom.com.tr
About Netsia:
Netsia, a US subsidiary of Argela, is based in Santa Clara, California in the heart of Silicon Valley. With key architects, engineers and product people, Netsia is developing leading edge solutions for the telecom industry. Netsia is in active participation with open source communities and standards bodies and provides enriched, telco-grade, and supported distributions of the open source platforms. www.netsia.com
About Zyxel Communications
Zyxel Communications delivers technological innovations and has connected the world to the internet for more than 30 years. Whether establishing access through fixed or mobile broadband solutions, Zyxel Communications offers a comprehensive and flexible portfolio of products that’s keeping service providers ahead of the competition. Come by our booth at MWC 2024 to know more about our solutions and partnerships: Homepage | EMEA | Zyxel
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227158748/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom